Long-term benefit of the TAXUS liberté stent in small vessels and long lesions - TAXUS ATLAS program

John A. Ormiston, Mark A. Turco, Jack J. Hall, Louis A. Cannon, Steven J. Yakubov, Michael J. Lucca, Gregg W. Stone, Charles D. O'Shaughnessy, Joseph A. Kozina, Ian C. Gilchrist, Barry D. Bertolet, Stephen G. Worthley, Paul L. Underwood, Keith D. Dawkins

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Background: The long-term impact of treating de novo coronary lesions in native vessels and challenging small vessel and long lesion subsets with TAXUS Liberté stents is unknown. This report examines the 3-year efficacy and safety from the TAXUS ATLAS program. Methods and Results: TAXUS ATLAS WH, Small Vessel, and Long Lesion are non-randomized studies comparing TAXUS Liberté (n=871), TAXUS Liberté 2.25 mm (n=261), and TAXUS Liberté 38 mm (n=150) stents, respectively, to case-matched TAXUS Express historical controls. TAXUS Liberté demonstrated comparable 3-year rates of major adverse cardiac events (19.0% vs. 20.2%, P=0.51) in de novo lesions, reduced target lesion revascularization (TLR, 10.0% vs. 22.1%, P=0.008) in small vessels, and reduced myocardial infarction (MI, 2.9% vs. 10.4%; P=0.01) and stent thrombosis (ST, 0.0% vs. 3.9%, P=0.03) in long lesions vs. TAXUS Express. After propensity score adjustment, no statistically significant effect of TAXUS Liberté on TLR (9.7% vs. 16.9%, P=0.12) in small vessels or MI (2.9% vs. 7.9%, P=0.05) in long lesions was noted, although reduced ST (0.0% vs. 2.7%, P=0.02) remained in long lesions. Multivariate analyses demonstrated that TAXUS Liberté treatment significantly reduced TLR by 66% in small vessels, and MI by 75% in long lesions, vs. TAXUS Express. Conclusions: TAXUS Liberté suggests durable 3-year effectiveness in reducing restenosis and improved clinical outcomes in small vessels and long lesions compared with TAXUS Express.

Original languageEnglish (US)
Pages (from-to)1120-1129
Number of pages10
JournalCirculation Journal
Issue number5
StatePublished - May 2011

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Long-term benefit of the TAXUS liberté stent in small vessels and long lesions - TAXUS ATLAS program'. Together they form a unique fingerprint.

Cite this